IntelGenx Begins Montelukast VersaFilm(TM) Dosing in Patients with Mild to Moderate Alzheimer's Disease in Phase 2a Study
Stock Information for IntelGenx Technologies Corp.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.